TW200605906A - Remedy for thrombopenia - Google Patents

Remedy for thrombopenia

Info

Publication number
TW200605906A
TW200605906A TW094113923A TW94113923A TW200605906A TW 200605906 A TW200605906 A TW 200605906A TW 094113923 A TW094113923 A TW 094113923A TW 94113923 A TW94113923 A TW 94113923A TW 200605906 A TW200605906 A TW 200605906A
Authority
TW
Taiwan
Prior art keywords
antihuman
activity
antibody
vb22b
found out
Prior art date
Application number
TW094113923A
Other languages
Chinese (zh)
Inventor
Masayuki Tsuchiya
Tetsuro Orita
Yoshihiro Matsumoto
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of TW200605906A publication Critical patent/TW200605906A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

By obtaining and purifying antihuman Mp1 antibody, antihuman Mpl sv(Fv)2 is purified with the use of a genetic engineering technique. Further, antihuman Mp1 sc(FV)2 is successfully humanized. By evaluating the TPO-like agonistic activity of sc(Fv)2, it is found out that sc(Fv)2 shows a high agonistic activity to antihuman Mp1 antibody and the activity is comparable or even superior to the activity of human TPO which is a natural ligand. It is also found out that VB22B sc(Fv)2 and humanized VB22B sc(Fv)2 have an effect of increasing platelets in vivo.
TW094113923A 2004-05-11 2005-04-29 Remedy for thrombopenia TW200605906A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004141618 2004-05-11

Publications (1)

Publication Number Publication Date
TW200605906A true TW200605906A (en) 2006-02-16

Family

ID=35320039

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094113923A TW200605906A (en) 2004-05-11 2005-04-29 Remedy for thrombopenia

Country Status (3)

Country Link
JP (1) JPWO2005107784A1 (en)
TW (1) TW200605906A (en)
WO (1) WO2005107784A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
JP4794301B2 (en) 2003-06-11 2011-10-19 中外製薬株式会社 Antibody production method
ES2592271T3 (en) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Polypeptide production methods by regulating the association of polypeptides
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
JP5085322B2 (en) 2005-06-10 2012-11-28 中外製薬株式会社 Pharmaceutical composition containing sc (Fv) 2
CA2611726C (en) * 2005-06-10 2017-07-11 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(fv)2
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CN105177091A (en) 2006-03-31 2015-12-23 中外制药株式会社 Antibody modification method for purifying bispecific antibody
KR20090021217A (en) 2006-06-14 2009-02-27 추가이 세이야쿠 가부시키가이샤 Hematopoietic stem cell proliferation promoter
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US9526713B2 (en) * 2013-05-24 2016-12-27 Kunming Shenghuo Pharmaceutical (Group) Co., Ltd. Use of dencichine in preparation of drug for treating thrombocytopenia
SG11201602261VA (en) 2013-09-27 2016-04-28 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09289892A (en) * 1996-04-25 1997-11-11 Yamanouchi Pharmaceut Co Ltd C-mpl ligand agonist antibody
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
CA2424364A1 (en) * 2000-10-20 2003-04-01 Chugai Seiyaku Kabushiki Kaisha Degraded tpo agonist antibody
CA2424371A1 (en) * 2000-10-20 2003-04-01 Chugai Seiyaku Kabushiki Kaisha Agonistic monoclonal antibody fragments
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity

Also Published As

Publication number Publication date
WO2005107784A1 (en) 2005-11-17
JPWO2005107784A1 (en) 2008-03-21

Similar Documents

Publication Publication Date Title
TW200605906A (en) Remedy for thrombopenia
BRPI0720462A2 (en) ABRASIVE COMPACTS WITH IMPROVED MACHINABILITY
UA104132C2 (en) Humanized antibodies against tl1a
WO2007024535A3 (en) Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
IL172321A (en) Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
NZ595225A (en) Use of tnf inhibitor for treatment of erosive polyarthritis
BRPI0417077A (en) anti-mpl antibodies
WO2007062245A3 (en) Human monoclonal antibody human cd134 (ox40) and methods of making and using same
IL181473A0 (en) Humanized anti-beta 7 antagonists and uses therefor
SG155205A1 (en) Interleukin-10 antibodies
GEP20166454B (en) Sclerostin binding agents
WO2007008712A8 (en) Anti-alpha v beta 6 antibodies and uses thereof
DK1755634T3 (en) Oligopeptides to decrease elevated blood urea concentration
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2143795A3 (en) Anti-CD20 monoclonal antibody
MY145073A (en) Anti-glypican 3 antibody
ATE518952T1 (en) BISPECIFIC ANTIBODY AS A REPLACEMENT FOR FACTOR VIII
WO2005014035A3 (en) Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
MX2009005743A (en) NEW Abeta CONFORMER SELECTIVE ANTI-Abeta GLOBULOMER MONOCLONAL ANTIBODIES.
EP1461081A4 (en) Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
EP1957675A4 (en) Systems and methods for the biometric analysis of index founder populations
SG146696A1 (en) Humanized antibodies against vascular endothelial growth factor
MY142988A (en) Novel aminobenzophenone compounds
IL171356A (en) Anti-interferon receptor antibody for treatment of inflammatory bowel disease